Gujarat Themis Biosyn
Gujarat Themis Biosyn Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Gujarat Themis Biosyn Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Gujarat Themis Biosyn Ltd trades at a P/E of 90.28× and P/B of 14.67×.
Valuation
Profitability
Growth
Financial Health
Gujarat Themis Biosyn Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Gujarat Themis Biosyn Ltd, switchable between annual and quarterly views, consolidated or standalone.
Gujarat Themis Biosyn Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,249.65 Cr and reported EPS of ₹4.29.
Gujarat Themis Biosyn segment analysis: revenue and profit mix.
Disclosed business segments at Gujarat Themis Biosyn with their share of revenue and profit, switchable between consolidated and standalone reporting.
Gujarat Themis Biosyn discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Gujarat Themis Biosyn Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Gujarat Themis Biosyn Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Gujarat Themis Biosyn Ltd's investment case rests on 8 positive markers and 7 flagged concerns drawn from the latest reported filings.
What you're getting.
The company demonstrates robust profitability with an impressive Return on Capital Employed (ROCE) of 27.30% and Return on Equity (ROE) of 21.70%, indicating efficient capital utilization and strong shareholder returns.
Gujarat Themis Biosyn maintains a very healthy financial structure, evidenced by its low Debt-to-Equity ratio of 0.12, suggesting minimal reliance on borrowed funds and strong financial stability.
A significant promoter holding of 70.9% signals strong confidence from the company's insiders in its future prospects and long-term value creation, aligning management and shareholder interests.
The company boasts a high Operating Profit Margin (OPM) of 43.40%, reflecting strong operational efficiency and effective cost management in its core business activities.
Foreign Institutional Investors (FIIs) have shown growing interest, increasing their stake from 2.51% in June 2025 to 2.95% in September 2025, indicating rising external investor confidence.
What can break it.
The stock trades at a very high Price-to-Earnings (P/E) ratio of 113.00, significantly above industry peers, suggesting potential overvaluation and limited upside at current levels.
The company reported a notable decline in recent quarterly sales by -7.62% and a substantial drop in net profit by -31.60%, raising concerns about short-term operational challenges.
With a Price-to-Book Value of 20.40, the stock is trading at a substantial premium to its intrinsic book value, which could imply a stretched valuation for investors.
Promoter holding decreased from 75.00% in 2023-09-01 to 70.87% in 2023-12-01, which might be perceived as a slight reduction in insider confidence or a move to meet public shareholding norms.
The company faces significant competitive pressure from much larger and established players in the pharmaceutical sector, such as Sun Pharma and Divi's Lab, with vastly superior resources and market reach.
What would change my mind.
Trim if P/E re-rates above 117. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 56.73. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 12%. The operating engine is no longer compounding capital efficiently.
Gujarat Themis Biosyn Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Gujarat Themis Biosyn Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Gujarat Themis Biosyn Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Gujarat Themis Biosyn Ltd — derived from the live tape, not yesterday's close.
Gujarat Themis Biosyn Ltd last traded at ₹387.3 with an intraday range of ₹381.05–₹392.4 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹387.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 415.48 | +28.18 | +7.28% |
| R3 | 404.13 | +16.83 | +4.35% |
| R2 | 398.27 | +10.97 | +2.83% |
| R1 | 392.78 | +5.48 | +1.42% |
| PIVOT | 386.92 | -0.38 | -0.10% |
| CURRENT | 387.30 | — | — |
| S1 | 358.73 | -28.57 | -7.38% |
| S2 | 370.08 | -17.22 | -4.45% |
| S3 | 375.57 | -11.73 | -3.03% |
| S4 | 381.43 | -5.87 | -1.51% |
GUJTHEM is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: 381.05 ~ 392.4
Trading Above opening range, showing Bullishness
Gujarat Themis Biosyn Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Gujarat Themis Biosyn Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Gujarat Themis Biosyn Ltd stood at 52.8% of traded volume, against a 20-day average of 42.5%.
Gujarat Themis Biosyn announcements: results, concalls, ratings, M&A.
Filings Gujarat Themis Biosyn sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Gujarat Themis Biosyn files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 73 documents below.
Copy of Newspaper Publication
Gujarat Themis Biosyn Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Gujarat Themis Biosyn Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange…
Investor Presentation
Gujarat Themis Biosyn Limited has informed the Exchange about Investor Presentation
Outcome of Board Meeting
Gujarat Themis Biosyn Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Copy of Newspaper Publication
Gujarat Themis Biosyn Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Gujarat Themis Biosyn dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Gujarat Themis Biosyn has declared, sequenced by announce and record date.
Gujarat Themis Biosyn corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Gujarat Themis Biosyn Ltd: business, sector, key facts.
What Gujarat Themis Biosyn Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Gujarat Themis Biosyn Ltd operates in the Healthcare, listed as NSE: GUJTHEM, BSE: 506879.
Gujarat Themis Biosyn Limited (GUJTHEM) is an Indian pharmaceutical company specializing in the manufacturing of pharmaceuticals and medicinal chemicals. Its primary operations are focused within India, contributing to the domestic pharmaceutical market.
A significant part of GUJTHEM's business model involves providing bulk drug manufacturing services on a job work basis. This means the company produces active pharmaceutical ingredients (APIs) for other pharmaceutical companies, acting as a contract manufacturer rather than solely focusing on producing and selling its own branded products. This outsourcing model allows GUJTHEM to leverage its manufacturing capabilities to serve a broader range of clients.
The company's product portfolio includes several key APIs, highlighting its expertise in specific therapeutic areas. Rifamycin-S, an intermediate used in the creation of tuberculosis treatments, is a prominent example. The production of Rifamycin-O, another important intermediate, also features prominently. Lovastatin, a cholesterol-lowering drug, represents another significant product within GUJTHEM's range. This diverse product mix showcases the company's capabilities in producing different types of APIs for various pharmaceutical applications.
Established in 1981 and headquartered in Mumbai, GUJTHEM has a long history in the Indian pharmaceutical industry. Its long operational history suggests a degree of experience and established manufacturing processes. The location in Mumbai positions it strategically within a major economic and industrial hub of India, facilitating access to resources, talent, and markets.
Questions investors ask about Gujarat Themis Biosyn Ltd (GUJTHEM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Gujarat Themis Biosyn Ltd (GUJTHEM)?
The current share price of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹387.3. Today, the stock has gained by ₹4.00 (1.04%), trading in a range of ₹381.05 to ₹392.4. The stock opened at ₹381.05 with a trading volume of 85,320 shares.
02Is Gujarat Themis Biosyn Ltd stock a good investment for long-term?
Gujarat Themis Biosyn Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,249.65 crores, P/E ratio of 90.28, ROE of 17.41%, and ROCE of 27.30%. The dividend yield stands at 0.17%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Gujarat Themis Biosyn Ltd stock?
The 52-week high price of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹0, while the 52-week low is ₹0. Currently trading at ₹387.3, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Gujarat Themis Biosyn Ltd stock at the current price?
Whether to buy Gujarat Themis Biosyn Ltd stock at ₹387.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 90.28 and P/B ratio of 14.67. Today's performance shows a gain of 1.04%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Gujarat Themis Biosyn Ltd and when is the next dividend?
Gujarat Themis Biosyn Ltd offers a dividend yield of 0.17%, which means for every ₹100 invested at the current price of ₹387.3, you can expect to receive approximately ₹0.17 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd's key financial metrics include: P/E Ratio: 90.28, P/B Ratio: 14.67, ROE: 17.41%, ROCE: 27.30%, Dividend Yield: 0.17%, EPS: ₹4.29, Book Value: ₹26.41, and Debt-to-Equity: 56.23. The company's market cap stands at ₹4,249.65 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Gujarat Themis Biosyn Ltd stock performing today in the market?
Gujarat Themis Biosyn Ltd stock opened at ₹381.05 and is currently trading at ₹387.3, showing a gain of ₹4.00 (1.04%). The intraday high is ₹392.4 and low is ₹381.05. The trading volume stands at 85,320 shares, indicating moderate market participation today.
08What is the P/E ratio of Gujarat Themis Biosyn Ltd and what does it indicate?
Gujarat Themis Biosyn Ltd has a Price-to-Earnings (P/E) ratio of 90.28, which means investors are willing to pay ₹90.28 for every ₹1 of earnings. With an EPS of ₹4.29, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Gujarat Themis Biosyn Ltd (GUJTHEM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- AHCL (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy